Subscribe
shutterstock_1821749396_rafapress
rafapress / Shutterstock.com
25 April 2023Big PharmaLiz Hockley

Cipla loses fightback over diarrhoea antibiotic

Judge rejects notion that tribunal acted unfairly in royalties dispute with Salix | Indian firm wanted payments on sales of antibiotic | Appeal brought under act with ‘high hurdle to surmount’.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Generics
Cipla files defensive patent suit over Ofev generic
8 March 2022   Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.


Editor's picks

BMS blocks biosimilar version of blockbuster cancer drug in India
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

Editor's picks

Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Generics
Cipla files defensive patent suit over Ofev generic
8 March 2022   Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

More on this story

Big Pharma
Exelixis takes Cipla to court over generic cancer drug
21 March 2023   Cipla claims Cabometyx patents are invalid | Exelixis wants generic blocked until at least 2030.
Generics
Cipla files defensive patent suit over Ofev generic
8 March 2022   Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

More features

European Patent Office’s G1/25 referral under the microscope
Pfizer loses UK appeal over Moderna Covid-19 vaccine patent
WATCH: UPC update—shaping patent litigation
Bayer’s Xarelto patent struck down by German court
Teva draws line under asthma inhaler feud with US rival
Xanax owner fends off ‘Canvax’ mark in EU
Four-lawyer team joins Cozen O’Connor’s new San Diego office
WATCH: Beyond patents — the evolving role of IP lawyers in life sciences